Ensysce Biosciences, Inc. (ENSCW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
7946 IVANHOE AVENUE LA JOLLA, CA 92037 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 1,124 | 3,148 | 12,265 | 49 | 1,061 | 1,658 | |||
| Cash and cash equivalent | 1,124 | 3,148 | 12,265 | 49 | 1,061 | 1,658 | |||
| Receivables | 98 | 277 | 442 | ||||||
| Prepaid expense | 1,068 | 1,847 | 2,931 | 157 | 139 | 87 | |||
| Other undisclosed current assets | 27 | 25 | 20 | 171 | |||||
| Total current assets: | 2,289 | 5,299 | 15,663 | 226 | 1,200 | 1,916 | |||
| Noncurrent Assets | |||||||||
| Asset, held-in-trust | 12,628 | 195,312 | 202,916 | ||||||
| Other noncurrent assets | 419 | 586 | 755 | ||||||
| Total noncurrent assets: | 419 | 586 | 755 | 12,628 | 195,312 | 202,916 | |||
| TOTAL ASSETS: | 2,708 | 5,885 | 16,417 | 12,855 | 196,512 | 204,832 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 2,478 | 5,170 | 3,709 | 260 | 2,771 | 438 | |||
| Accounts payable | 1,936 | 2,944 | 301 | 2,771 | 429 | ||||
| Accrued liabilities | 542 | 2,226 | 3,408 | 9 | |||||
| Other undisclosed accounts payable and accrued liabilities | 260 | ||||||||
| Debt | 855 | 4,267 | 12,748 | ||||||
| Other undisclosed current liabilities | 27 | 25 | |||||||
| Total current liabilities: | 3,333 | 9,464 | 16,482 | 260 | 2,771 | 438 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 450 | 8,094 | 791 | 566 | |||||
| Long-term debt, excluding current maturities | 450 | 8,094 | 791 | 566 | |||||
| Liabilities, other than long-term debt | 26 | 2 | |||||||
| Deferred tax liabilities, net | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 2 | ||
| Other liabilities | 26 | ||||||||
| Other undisclosed noncurrent liabilities | 13,010 | 7,000 | 7,000 | ||||||
| Total noncurrent liabilities: | 26 | 450 | 8,094 | 13,801 | 7,566 | 7,002 | |||
| Total liabilities: | 3,359 | 9,915 | 24,575 | 14,062 | 10,337 | 7,440 | |||
| Temporary equity, including noncontrolling interest | 181,175 | 192,392 | |||||||
| Equity | |||||||||
| Equity, attributable to parent | (323) | (3,714) | (7,878) | (1,207) | 5,000 | 5,000 | |||
| Common stock | 0 | 1 | 2 | 1 | 1 | 1 | |||
| Additional paid in capital | 121,234 | 107,216 | 77,965 | 2,543 | 2,909 | ||||
| Retained earnings (accumulated deficit) | (121,557) | (110,931) | (85,846) | (1,208) | 2,457 | 2,091 | |||
| Equity, attributable to noncontrolling interest | (328) | (315) | (280) | ||||||
| Total equity: | (651) | (4,030) | (8,158) | (1,207) | 5,000 | 5,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 2,708 | 5,885 | 16,417 | 12,855 | 196,512 | 204,832 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 2,231 | 2,523 | 3,531 | |||||
| Gross profit: | 2,231 | 2,523 | 3,531 | |||||
| Operating expenses | (12,949) | (26,745) | (23,402) | (1,369) | (3,329) | |||
| Other undisclosed operating loss | (959) | |||||||
| Operating loss: | (10,718) | (24,222) | (19,870) | (1,369) | (3,329) | (959) | ||
| Nonoperating income (expense) | 92 | 14 | (9,275) | 5,924 | 4,250 | 3,635 | ||
| Other nonoperating income (expense) | 15 | 86 | (437) | 5,924 | 4,250 | 3,635 | ||
| Interest and debt expense | (354) | (3,965) | (1,295) | |||||
| Income (loss) from continuing operations before income taxes: | (10,980) | (28,172) | (30,441) | 4,555 | 921 | 2,676 | ||
| Income tax expense | (244) | (555) | (554) | |||||
| Income (loss) from continuing operations: | (10,980) | (28,172) | (30,441) | 4,311 | 366 | 2,122 | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (30,441) | 4,311 | 366 | 2,122 | |
| Other undisclosed net income | 354 | 3,965 | 1,295 | |||||
| Net income (loss): | (10,626) | (24,208) | (29,146) | 4,311 | 366 | 2,122 | ||
| Net income attributable to noncontrolling interest | 13 | 35 | 62 | |||||
| Net income (loss) attributable to parent: | (10,613) | (24,172) | (29,084) | 4,311 | 366 | 2,122 | ||
| Preferred stock dividends and other adjustments | (13) | (913) | (3,240) | (3,465) | ||||
| Other undisclosed net loss available to common stockholders, basic | (803) | |||||||
| Net income (loss) available to common stockholders, diluted: | (10,626) | (25,085) | (29,887) | 4,311 | (2,874) | (1,343) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (10,626) | (24,208) | (29,146) | 4,311 | 366 | 2,122 | ||
| Comprehensive income (loss): | (10,626) | (24,208) | (29,146) | 4,311 | 366 | 2,122 | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 13 | 35 | 62 | |||||
| Comprehensive income (loss), net of tax, attributable to parent: | (10,613) | (24,172) | (29,084) | 4,311 | 366 | 2,122 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.